TY - JOUR T1 - Epigenetic alterations in the circulating DNA from blood of patients with COPD and lung cancer JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - P538 AU - Anastasia Ponomaryova AU - Elena Rykova AU - Nadezda Cherdyntseva AU - Tatiana Skvortsova AU - Alexey Dobrodeev AU - Alexander Zav'yalov AU - Sergey Tuzikov AU - Valentin Vlassov AU - Pavel Laktionov Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/P538.abstract N2 - Background: Epigenetic changes were shown to be detectable in DNA, circulating in blood (cirDNA) of cancer patients, indicating the resources to create the minimally invasive diagnostic tests based on tumor-specific DNA markers.Methods: Blood samples were taken from 60 untreated patients with non-small-cell lung cancer (NSCLC), 30 patients with chronic obstructive pulmonary disease (COPD) and 32 healthy subjects. Methylation level of tumor suppressor genes (RARB2, RASSF1A) and repetitive elements (LINE-1) in the cirDNA from blood plasma and cirDNA eluated from blood cell surface (csb-cirDNA) with PBS/EDTA and trypsin solutions was assessed by quantitative methylation-specific PCR.Results: Methylation level of RASSF1A and RARB2 genes were 2-3 fold higher in cirDNA from NSCLC patients compared with healthy subjects (Mann-Whitney U test, P<0.05). If at least one from RASSF1A or RARB2 methylation level exceeded the cut-off values NSCLC patients were discriminated from healthy subjects with sensitivity and specificity of 90% and 82% when both plasma cirDNA and csb-cirDNA were analyzed. Discrimination of NSCLC from COPD patients was characterized by 88% sensitivity and 80% specificity. Values of RARB2 methylation level significantly increased in csb-cirDNA and plasma cirDNA from COPD and NSCLC patients compared with healthy subjects (P<0.05). RASSF1 methylation in plasma cirDNA and csb-cirDNA did not differ between COPD and healthy subjects. RARB2 methylation level increase was associated with advanced stage of NSCLC. The data of LINE-1 methylation in both fractions of cirDNA from NSCLC and COPD patients’ blood will be presented at the congress. ER -